Compare Fubotv Inc (FUBO) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs Mesoblast Limited — how do they compare? Fubotv Inc trades at $9.29 (market cap $1.06B), while Mesoblast Limited trades at $16.86 (market cap $2.21B). The key difference: Mesoblast Limited is far larger — about 2.1× Fubotv Inc's market cap, and Mesoblast Limited is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals.
| FUBO | MESO | |
|---|---|---|
Market Cap | $1.06B | $2.21B |
Sector | Technology | Technology |
52-Week High | $54.72 | $20.96 |
52-Week Low | $8.09 | $12.88 |
Enterprise Value | $1.23B | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $9.46, up 1.07% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q3 2026 revenue of $1.48 billion (Business Wire, 2026-08-05) and raised its full-year adjusted EBITDA target to $90–$100 million. Valuation ratios appear attractive with a P/S of 0.19 and P/B of 0.36, while recent earnings showed mixed results with two beats and one miss in the last four quarters.
The outlook is cautiously optimistic with analyst consensus pointing to significant upside to a $15.33 price target. Key opportunities include subscriber growth from live sports and advertising improvements, but risks persist from negative cash flows and high debt levels. Execution under new CEO Alisa Bowen and partnerships with Disney and NBCUniversal are critical for achieving profitability targets.
MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.
The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
